Vincristine

Vincristine 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Diffuse Large B-cell Lymphoma、Peripheral T Cell Lymphoma、DLBCL - Diffuse Large B Cell Lymphoma、Angioimmunoblastic T-cell Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Vincristine 研究

• Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer

  II 期招募中中国NCT06088030

• Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

  I 期招募中美国NCT04301076

• DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

  I 期 / II 期招募中中国NCT07059650

• Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  III 期招募中美国澳大利亚加拿大新西兰NCT03959085

• Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL

  I 期 / II 期招募中中国NCT06760039

• Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

  不适用招募中美国NCT04199026

• A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

  不适用招募中中国NCT05899621

• Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma

  I 期 / II 期招募中中国NCT06829771

• Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

  I 期 / II 期招募中中国NCT04432714

• FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

  I 期 / II 期招募中澳大利亚奥地利比利时CzechiaNCT04625907

• Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.

  II 期招募中中国NCT06514313

• The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk

  III 期招募中中国NCT05018520

• Venetoclax Basket Trial for High Risk Hematologic Malignancies

  I 期招募中美国NCT05292664

• Modified CV Regimen in Optic Pathway Glioma

  II 期招募中中国NCT05278715

• A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

  II 期 / III 期招募中美国Argentina澳大利亚ChileNCT07634471

• A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

  III 期招募中美国加拿大Puerto RicoNCT04166409

• Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

  II 期招募中美国NCT04803201

• A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients

  II 期招募中中国NCT06569485

• Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  早期 I 期招募中美国澳大利亚加拿大德国NCT06333899

• Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene Abnormalities

  I 期招募中中国NCT07888114

• Transplantation After Complete Response In Patients With T-cell Lymphoma

  不适用招募中法国NCT05444712

• Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  II 期招募中美国NCT03136146

• Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)

  II 期招募中中国NCT06347653

• Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

  III 期招募中美国澳大利亚加拿大新西兰NCT05304585

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。